Nava provides a modular lipid nanoparticle (LNP) platform engineered for organ‑ and cell‑type‑specific delivery of RNA therapeutics, including mRNA, siRNA, and antisense oligonucleotides. By using rationally designed lipid chemistries, the platform achieves high encapsulation efficiency, precise tropism, and scalable GMP‑compatible manufacturing, enabling pharmaceutical and biotech partners to deliver RNA medicines at clinically relevant doses with reduced off‑target exposure.
Funding
Funding not disclosed
Founders
Product
Problem
RNA therapeutics require delivery vehicles that can transport nucleic acids safely to specific organs and cell types at doses sufficient for clinical effect. Existing lipid nanoparticle (LNP) systems often distribute broadly, leading to off‑target exposure, reduced efficacy, and safety concerns, which limits treatment options for many serious diseases.
Solution
Nava has created a modular LNP platform engineered through rational design to exhibit selective tissue tropism. By exploring novel chemical space, the company produces LNP formulations that preferentially target a wide range of organs and cellular subsets, enabling precise and efficient RNA delivery. This targeted approach allows RNA‑based medicines to reach the intended site of action at clinically relevant doses while minimizing off‑target effects. The platform is intended to support diverse RNA modalities—including mRNA, siRNA, and antisense oligonucleotides—across therapeutic areas with high unmet medical need. Nava’s technology aims to expand the range of treatable conditions by overcoming the delivery barrier that currently restricts many genetic medicines.
Target Audience
Primary customers are pharmaceutical and biotech companies developing RNA‑based therapeutics that require targeted delivery to specific organs or cell populations.
Features
- Rationally designed lipid chemistries that confer organ‑specific and cell‑type‑specific tropism
- Modular LNP architecture allowing rapid formulation of different RNA payloads (mRNA, siRNA, etc.)
- High encapsulation efficiency and stability to maintain RNA integrity during circulation
- Scalable manufacturing process compatible with GMP production for clinical development
- Preclinical data demonstrating precise delivery and therapeutic efficacy in multiple tissue models